TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Stephen Webster to its Board of Directors. With nearly 30 years of biotechnology industry experience in raising capital, business development transactions and operations, Mr. Webster has played important roles as the Chief Financial Officer of Spark Therapeutics, Optimer Pharmacuticals and Adolor Corporation. In connection with Mr. Webster’s arrival, Mitchell Finer, Ph.D., will be stepping down from the Board of Directors effective May 4, 2020 but will continue to serve TCR2 in an advisory capacity.

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place June 22-24, 2020. The e-poster presentation will highlight preclinical data of the Company’s proprietary T Cell Receptor Fusion Construct (TRuC®) T cells that co-express a PD-1:CD28 switch receptor, which acts as a cell-intrinsic mechanism to overcome PD-L1/PD-L2 mediated immunosuppression. Upon repeated antigen stimulation, co-expression of the switch receptor in mesothelin-targeting TC-210 T cells enhanced TCR downstream signaling, prevented PD-L1-mediatied functional T-cell inhibition, significantly increased proliferation and augmented the production of growth and effector cytokines.

TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Angela Justice, Ph.D., as its first Chief People Officer. “We are delighted to announce the appointment of Angela to the TCR2 executive team,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. Over the course of her career, Angela has consistently focused on improving the employee experience by providing clarity of purpose, measurable metrics and resources for continuous learning.

CAMBRIDGE, Mass., Feb. 18, 2020 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

If you want to know who really controls TCR2 Therapeutics Inc. (NASDAQ:TCRR), then you'll have to look at the makeup...

Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020Continued progress of TC-110 with.

CAMBRIDGE, Mass., Nov. 12, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Axel Hoos, M.D., Ph.D., to its Board of Directors. An immuno-oncology pioneer with broad business and scientific expertise, Dr. Hoos is recognized for launching the field through development of the anti-CTLA-4 ipilimumab, the first FDA-approved checkpoint immunotherapy. "With TCR2 at a significant inflection point in the growth of its clinical pipeline and platform, we are delighted to announce that Axel Hoos, one of the most respected industry leaders in oncology, will be joining our Board of Directors," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.

TCR2 Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

CAMBRIDGE, Mass., Jan. 07, 2020 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

CAMBRIDGE, Mass., Aug. 30, 2019 -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

CAMBRIDGE, Mass., April 03, 2020 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

Company initiated Phase 1/2 clinical trial for TC-110, its lead hematological malignancy candidateInterim update from Phase 1 portion of TC-210 Phase 1/2 trial anticipated in.

CAMBRIDGE, Mass., Sept. 27, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.

As of late, it has definitely been a great time to be an investor in TCR2 Therapeutics Inc. (TCRR).

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced an expansion of its leadership team to strengthen expertise in business development and regulatory affairs as the Company advances the development of TRuC®-T cells addressing solid tumors and hematological malignancies. “As we position TCR2 for our next phase of growth and value creation, we are pleased to announce the addition of experienced leaders in two key competencies – business development and regulatory affairs,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. “Clinical progress and the execution of strategic partnerships are important priorities for the Company and having the right expertise in both domains is critical for our success.”

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present a poster at the 2020 Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond, taking place February 8-10, 2020 in Banff, Canada. The presentation will highlight allogeneic (off-the-shelf) T Cell Receptor Fusion Constructs (TRuC®) T cells. In addition to utilizing TCR2’s proprietary TRuC-T cell platform, the approach employs CRISPR/Cas9 endonucleases yielding fully functional TRuCs that lack alloreactivity and upregulate activation markers, secrete cytokines and kill tumor cells in an antigen-specific manner.